IntelGenx to Report First Quarter 2022 Financial Results on May 12, 2022 – Conference Call to Follow
05 mai 2022 16h30 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, May 05, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its...
IntelGenx to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference
26 avr. 2022 16h45 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, April 26, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that management will...
IntelGenx Reports Fourth Quarter and Full-Year 2021 Financial Results
24 mars 2022 16h03 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 24, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and...
IntelGenx to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022 – Conference Call to Follow
17 mars 2022 16h30 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, March 17, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release...
IntelGenx Receives Third Loan Tranche from atai
01 févr. 2022 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Further to its press release dated September 15, 2021, IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company”) today announced that its...
First Patient Dosed in IntelGenx’s Resumed ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
20 janv. 2022 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Jan. 20, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”), a leader in pharmaceutical films, today announced that patient dosing...
IntelGenx Initiates Arbitration Proceeding Against Tilray® Related to an Alleged Breach of Worldwide Cannabis-Infused VersaFilm® Agreement
08 déc. 2021 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 08, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has initiated an arbitration proceeding against...
IntelGenx Reports Third Quarter 2021 Financial Results
11 nov. 2021 16h03 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 11, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter...
IntelGenx to Report Third Quarter 2021 Financial Results on November 11, 2021 – Conference Call to Follow
04 nov. 2021 16h30 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its...
Patient Screening to Resume in IntelGenx’s ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
12 oct. 2021 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Oct. 12, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Company”)), a leader in pharmaceutical films, today announced its intention to...